Comparative Pharmacology
Head-to-head clinical analysis: AEROSEB DEX versus NUTRACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROSEB DEX versus NUTRACORT.
AEROSEB-DEX vs NUTRACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The combination product contains a corticosteroid (dexamethasone) which suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and a topical antibiotic (usually neomycin or polymyxin B) which inhibits bacterial protein synthesis or disrupts bacterial cell membranes.
Corticosteroid receptor agonist; induces anti-inflammatory proteins and suppresses inflammatory mediators.
2 puffs (100 mcg each) intranasally twice daily
One capsule (200 mg) orally twice daily with meals.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life: 2-4 hours (mean 3 hours). Clinically, dosing every 6-8 hours maintains therapeutic levels.
Renal elimination of unchanged drug accounts for 30-40% of the dose; fecal/biliary elimination is 50-60% as metabolites. Less than 10% is excreted unchanged in feces.
Renal (primarily as glucuronide and sulfate conjugates, <10% unchanged) and fecal (biliary excretion of metabolites). Approximately 70-80% renal, 20-30% fecal.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid